NO950049L - Utfelling av en eller flere aktive forbindelser in situ - Google Patents

Utfelling av en eller flere aktive forbindelser in situ

Info

Publication number
NO950049L
NO950049L NO950049A NO950049A NO950049L NO 950049 L NO950049 L NO 950049L NO 950049 A NO950049 A NO 950049A NO 950049 A NO950049 A NO 950049A NO 950049 L NO950049 L NO 950049L
Authority
NO
Norway
Prior art keywords
situ
active compounds
precipitation
solution
administration
Prior art date
Application number
NO950049A
Other languages
English (en)
Norwegian (no)
Other versions
NO950049D0 (no
Inventor
Fredrik Broberg
Arne Brodin
Lisbet Rydhag
Sylvan G Frank
Original Assignee
Astra Ab
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab, Univ Ohio State Res Found filed Critical Astra Ab
Publication of NO950049D0 publication Critical patent/NO950049D0/no
Publication of NO950049L publication Critical patent/NO950049L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO950049A 1992-07-09 1995-01-05 Utfelling av en eller flere aktive forbindelser in situ NO950049L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9202128A SE9202128D0 (sv) 1992-07-09 1992-07-09 Precipitation of one or more active compounds in situ
PCT/SE1993/000566 WO1994001087A1 (fr) 1992-07-09 1993-06-24 Precipitation in situ d'un ou de plusieurs composes actifs

Publications (2)

Publication Number Publication Date
NO950049D0 NO950049D0 (no) 1995-01-05
NO950049L true NO950049L (no) 1995-01-05

Family

ID=20386754

Family Applications (1)

Application Number Title Priority Date Filing Date
NO950049A NO950049L (no) 1992-07-09 1995-01-05 Utfelling av en eller flere aktive forbindelser in situ

Country Status (16)

Country Link
US (1) US5916583A (fr)
EP (1) EP0648112B1 (fr)
JP (1) JP3809186B2 (fr)
AT (1) ATE196990T1 (fr)
AU (1) AU676177B2 (fr)
CA (1) CA2139505C (fr)
DE (1) DE69329576T2 (fr)
DK (1) DK0648112T3 (fr)
ES (1) ES2152255T3 (fr)
FI (1) FI950074L (fr)
GR (1) GR3035220T3 (fr)
IS (1) IS4037A (fr)
NO (1) NO950049L (fr)
PT (1) PT648112E (fr)
SE (1) SE9202128D0 (fr)
WO (1) WO1994001087A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2138130T3 (es) 1995-10-28 2000-01-01 Braun Melsungen Ag Composicion farmaceutica que contiene un anestesico local y/o un analgesico de accion central.
FR2748207B1 (fr) 1996-05-06 1998-06-12 Cird Galderma Composition a base d'un compose modulant la reactivite des fibres nerveuses
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
JP4865183B2 (ja) * 2000-06-06 2012-02-01 レキオファーマ株式会社 病変異常組織治療用医薬組成物キット
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US7193084B2 (en) 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
CN1558755A (zh) 2001-09-26 2004-12-29 ���ع��ʹ�˾ 通过分散和除去溶剂或液相制备亚微米大小的纳米颗粒
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
NZ531460A (en) * 2001-10-19 2005-05-27 Idexx Lab Inc Controlled release - over at least 4-15 days - of injectable compositions comprising a lipophilic counterion such a saturated or unsaturated C10-C18 fatty acid
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
FR2862872A1 (fr) * 2003-12-02 2005-06-03 Palbian Snc Composition a l'etat aqueux pour l'application perfusable d'un principe actif, notamment pharmacologique tel que le paracetamol.
US7402320B2 (en) * 2004-08-31 2008-07-22 Vnus Medical Technologies, Inc. Apparatus, material compositions, and methods for permanent occlusion of a hollow anatomical structure
WO2006081238A2 (fr) 2005-01-25 2006-08-03 Vnus Medical Technologies, Inc. Structures pour l'occlusion permanente d'une structure anatomique creuse
US20060280786A1 (en) * 2005-06-14 2006-12-14 Rabinow Barrett E Pharmaceutical formulations for minimizing drug-drug interactions
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
US8465451B2 (en) 2005-06-22 2013-06-18 Covidien Lp Methods and apparatus for introducing tumescent fluid to body tissue
CA2628630A1 (fr) * 2005-11-15 2007-05-24 Baxter International Inc. Compositions d'inhibiteurs de lipoxygenase
US9017361B2 (en) 2006-04-20 2015-04-28 Covidien Lp Occlusive implant and methods for hollow anatomical structure
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
CA2914608A1 (fr) * 2013-03-14 2014-09-25 Jsn I, Llc Masquage du gout d'anesthesiques et d'analgesiques
LT3049055T (lt) * 2013-09-27 2018-07-25 Anteis S.A. Injekcinio hidrogelio, sterilizuoto karščiu, sudaryto iš hialurono rūgšties, turinčio miltelių pavidalo lidokaino ir šarminio agento, gamybos būdas
US20160367959A1 (en) * 2015-06-18 2016-12-22 Avon Products, Inc. Multiphase Compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4268495A (en) * 1979-01-08 1981-05-19 Ethicon, Inc. Injectable embolization and occlusion solution
US4259331A (en) * 1979-04-16 1981-03-31 Pfizer Inc. Oxytetracycline compositions
US4599354A (en) * 1985-03-11 1986-07-08 Morton Shulman Composition and method for producing prolonged pain relief
US4775659A (en) * 1985-08-19 1988-10-04 Eli Lilly And Company Injectable semi-solid formulations
US5051257A (en) * 1989-05-09 1991-09-24 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
IT1242642B (it) * 1990-04-17 1994-05-16 Alfa Wassermann Spa Formulazioni iniettabili contenenti naproxen sale sodico.

Also Published As

Publication number Publication date
US5916583A (en) 1999-06-29
NO950049D0 (no) 1995-01-05
JP3809186B2 (ja) 2006-08-16
FI950074A0 (fi) 1995-01-05
PT648112E (pt) 2001-01-31
FI950074A7 (fi) 1995-01-05
AU676177B2 (en) 1997-03-06
DE69329576D1 (de) 2000-11-23
AU4519493A (en) 1994-01-31
CA2139505C (fr) 2003-10-28
WO1994001087A1 (fr) 1994-01-20
GR3035220T3 (en) 2001-04-30
SE9202128D0 (sv) 1992-07-09
ATE196990T1 (de) 2000-11-15
IS4037A (is) 1994-01-10
EP0648112A1 (fr) 1995-04-19
DE69329576T2 (de) 2001-03-08
EP0648112B1 (fr) 2000-10-18
FI950074L (fi) 1995-01-05
DK0648112T3 (da) 2000-11-27
ES2152255T3 (es) 2001-02-01
CA2139505A1 (fr) 1994-01-20
JPH07509450A (ja) 1995-10-19

Similar Documents

Publication Publication Date Title
NO950049L (no) Utfelling av en eller flere aktive forbindelser in situ
DE59108930D1 (de) Cyclische Iminoderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU557184B2 (en) Stabilized injectable solutions of piroxicam by addition of d-c-(-)-methylglucamine
RU94046169A (ru) Гетероциклические соединения, способ их получения, способ разделения оптических изомеров, фармкомпозиция, способ лечения
DE59308940D1 (de) Cyclische Iminoderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
KR860009007A (ko) 피페리딜리덴 디하이드로-디벤조[a,d]-사이클로헵텐의 제조방법
NO943895D0 (no) Galantaminderivater, en fremgangsmåte for fremstilling samt deres anvendelse som medikamenter
FR2649110B1 (fr) Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NO961236L (no) Pyrrolodiazin-derivater som stabilisatorer for klorholdige polymerisater
ES2160726T3 (es) Derivados de piperazin-2,5-diona como moduladores de resistencia a multiples farmacos.
FI103046B1 (fi) Menetelmä lääkeaineina käyttökelpoisten pyrrolidinyylitiokarbapeneemijohdannaisten valmistamiseksi
BE856578A (fr) Nouveaux derives de l'acide cyanurique, utilisables pour la stabilisation de matieres organiques
IT1265077B1 (it) Derivati del cicloeptimmidazolo, metodo per la loro produzione e agenti terapeutici contenenti questi composti
EA199900510A1 (ru) Инъекционное лекарственное средство "цитофлавин", обладающее цитопротекторным действием
KR890012990A (ko) 삼치환된 아민 이들의 제법 및 이들을 함유하는 제약조성물
GB1497266A (en) Aryloxy-and arylthio-alkanoates having cholesterol-reducing properties
ATE215934T1 (de) Neue histidinderivate, verfahren zu ihrer herstellung und ihre verwendung als mittel gegen freie radikale
KR890006651A (ko) 리파마이신 유도체
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법
CS247287A2 (en) Method of injection applicable water solutions antimetic agent stabilization
IE33249B1 (en) Substituted indolines
RO91015B1 (ro) Solutie injectabila de uz pediatric
MX9605694A (es) Metodo para estabilizar derivados de duocarmicina.
GB1159133A (en) Improvements in or relating to Benzothiopyrano-Pyridine Derivatives
GB1050249A (fr)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application